Novartis International Ag - Company Profile - 3015 Words

TABLE OF CONTENTS I. INTRODUCTION 1 II. COMPANY HISTORY 1 III. CHIEF EXECUTIVE OFFICER 2 IV. MAJOR PRODUCTS 3 V. MAJOR COMPETITORS 5 VI. SALES HISTORY 6 VII. MAJOR FACTORS AFFECTING INVESTMENT POTENTIAL 7 VIII. STOCK PRICE DATA AND INVESTMENT ANALYSIS 8 IX. CONCLUSIONS RECOMMENDATIONS 10 EXECUTIVE SUMMARY This company profile provides a preliminary investigation and analysis of Novartis International AG, a multinational pharmaceutical company based in Basel, Switzerland. Novartis is one of ten companies the Investment Board will consider for further in-depth research for a multimillion-dollar investment. Novartis was created in 1996 from the merger of two Swiss-based chemical/life sciences giants;†¦show more content†¦Additionally in 2003, Novartis acquired the worldwide adult medical nutrition business of Mead Johnson Company, a subsidiary of Bristol-Myers Squibb. In 2004, Novartis acquired two generics companies: the Danish company Durasacan A/S from AstraZeneca plc and Sabex Holdings Ltd of Canada. In 2005, Novartis acquired Hexal AG and Eon Labs, creating the world leader in generics. Additionally in 2005, Novartis acquired North American OTC brand portfolio from Bristol-Myers Squibb, and divested its Nutrition Santà © unit. In 2006, Novartis acquired the California-based Chiron Corporation. As of April of this year, Novartis is reportedly selling off its non-healthcare businesses to Nestlà © who has agreed to purchase Novartis medical nutrition business for $2.5 billion and its Gerber baby products business for $5.5 billion. Currently, Novartis is comprised of four business divisions: pharmaceuticals, vaccines and diagnostics, Sandoz Generics, and consumer health. The company’s mission is to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. III. CHIEF EXECUTIVE OFFICER Dr. Daniel Vasella is Chairman and Chief Executive Officer of Novartis. He was appointed Chairman in 1999 and has served as CEO and executive member of the Board of Directors since the merger that created Novartis in 1996. Dr. Vasella is also a member ofShow MoreRelatedInternational Business Systems And Porter s Diamond Model1258 Words   |  6 PagesPorter’s Diamond Model provides companies with four reliant factors that fully depend on the state of each other to achieve success within a competitive environment. However, Curran (2001) claims that Porter’s Diamond Model does not fully explain a country’s competitive advantage since only two factors provide evidence of their competitive position. The used factors are company rivalry, strategy, and factor endowments. With reference to the competitive positions of countries within major economiesRead MoreManagement Development in Ciba-Geigy Ltd. (Novartis)3248 Words   |  13 PagesCOURSE TITLE : â€Å"Human R esource Management† . COURSE CODE : EM-553. A Case Study On Management Development in Ciba-Geigy Ltd. (Novartis) Submitted To Professor Dr. Shahid U Ahmed Department of Management University of Dhaka Submitted By Md. Muyedul Islam ID # 3-09-16-034 Tahmina Afnan ID # 3-09-17-037 A.K.M. Majharul Huque Talukder ID # 3-09-16-021 Md. Farid Uddin ID # 3-09-16-028 Muhammad Abdul Malek ID # 3-09-16-019 HasanuzzamanRead MoreEli Lilly in India3134 Words   |  13 PagesIndia: Rethinking the Joint Venture Strategy Executive Summary Eli Lilly and Company is a pharmaceutical company, founded in 1876, that integrates many departments and supply-chain management.    The company in itself discovers, develops, manufactures, and sells a broad line of human health and agricultural products (Lilly.com). Eli Lilly had grown to become one of the leading pharmaceutical companies in the United States, and by 1992 its products were being manufactured and distributedRead MorePharmaceutical Industry Ethical Practices13569 Words   |  55 Pagesof Pakistan as a whole. The operations that take place in the Pharmaceutical Sector could be understood. The purpose also included the facts that could be disclosed which make a company competitive as compared to others in terms of Pharmaceutical Marketing. In understanding all these features of the Pharmaceutical Companies, Mr. Owais Baig, Mr. Zaigham Masood Sheikh, Dr. Yasir Saeed, Dr. Aun helped us. With this opportunity our group would like to thank them for providing us all the valuable informationRead MoreNestle Business Policy7372 Words   |  30 PagesGroup members: AberAhmed Alice Chen YuXin Bong Kern Yih DongHyunKim Edward Setyadarma Salman Kamani Executive Summary Nestlà © is currently the biggest food and beverages (Famp;B) company in the world. The company has a long-standing history of 140 years and a business portfolio comprising of more than 140 brands under the umbrella of Nestlà ©. One of Nestlà ©Ã¢â‚¬â„¢s cash cow product lines is the ice cream. Popular household ice cream brands under Nestlà © include Hà ¤agen-Dazs, Movenpick and Dreyer’sRead MoreVista7310 Words   |  30 PagesHelbling Holding AG Helbling - a Leader in Technological Innovation and Business Consulting Helbling Group Key figures 2012 ï  ® We are unique through our ability to integrate a spectrum of professional know-how, experience and skills. ï  ® 458 employees ï  ® Our ability to link technological expertise with business competence results in entrepreneurial success for our clients. ï  ® Companies in Switzerland, Germany, USA and China ï  ® Revenues CHF 110.9m ï  ® International Network OfficesRead MoreCsr Communication in the Pharma Industry35538 Words   |  143 Pagescommunication 2.1.3. Organization and functions of corporate communication 2.1.4. Corporate Communication as a management function 2.2. Corporate Social Responsibility 2.2.1. Towards a definition of CSR 2.2.2. Organizations and CSR involvement 2.2.2.1. Why companies engage in Corporate Social Responsibility? 2.2.2.2. Involvement levels on CSR 2.2.2.3. CSR and Corporate Communication: a strategy of visibility 2.2.3. Communicating CSR 2.2.3.1. Challenges of CSR communication 2.2.3.2. CSR Communication strategiesRead MoreManagement and Teaching Note19520 Words   |  79 Pages31,000 full text inspection copies. ecch provides a free monthly e-mail update service giving details of new cases from all sources. Visit www.ecch.com to subscribe. Economics, Politics and Business Environment 9-407-049 ALLIANZ AG: BECOMING A EUROPEAN COMPANY Lorsch, JW; Chernak, A Harvard Business School Publishing 20pp 205-024-4 BRITISH CHOCOLATE MARKET: UP FOR A FAIRTRADE ORGANIC MAKEOVER? Structured assignment Rathore, RS; Ragu, SP IBSCDC 15pp; Teaching note 205-024-8 (12pp) 207-057-1 BURGEONINGRead MoreMarketing Project of Reckitt Benckiser19417 Words   |  78 PagesMarketing Sales Finance Operational INTRODUCTION TO COMPANY Reckitt Benckiser is a British global consumer goods company, making and marketing home, health and personal care products. Headquartered in Slough, near London, UK, it has operations in over 60 countries, including 42 manufacturing facilities, and sales in nearly 200countries. RB is ranked 6th in the 2008 European Business Week 50, the magazines annual ranking of the best performing companies within the Samp;P European 350.The companys strategyRead MoreBsiness Strategy of Pepsico9186 Words   |  37 Pagesover  160 countries. The company has an extremely positive outlook for India. This reflects that India holds a central position in Pepsi s corporate strategy. India is a key market for Pepsi co, and at the same time the company has added value to Indian agriculture and industry. PepsiCo entered India in 1989 and is concentrating in three focus areas - Soft drink concentrate, snack foods and vegetable and food processing. Faced with the existing policy framework at the time, the company entered the Indian